Physician profile
Timothy D Blecha
NPI 1790777936
$3,493.21
in general payments reported to CMS, 2019-2025
31 companies · $385 in 2025
The $385 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $505 · 2020: $75.71 · 2021: $533 · 2022: $745 · 2023: $493 · 2024: $757 · 2025: $385.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,635.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,635.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $850.47 | 2019-2025 | Evenity, Prolia, Repatha |
| Abbvie INC. | $583.74 | 2021-2025 | Vraylar, Ubrelvy |
| Otsuka America Pharmaceutical, INC. | $403.34 | 2022-2025 | Rexulti |
| Novo Nordisk INC | $323.14 | 2019-2025 | Ozempic, Rybelsus |
| Pfizer INC. | $271.42 | 2019-2022 | |
| Lilly USA, LLC | $151.54 | 2021-2024 | Mounjaro |
| Janssen Pharmaceuticals, INC | $121.16 | 2019-2025 | Spravato |
| Gilead Sciences, INC. | $111.52 | 2024-2025 | Epclusa |
| Astellas Pharma US INC | $108.15 | 2019-2024 | Veozah |
| Lundbeck LLC | $64.34 | 2023-2025 | Rexulti |
| Allergan, INC. | $61.84 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $59.00 | 2025 | Caplyta |
| Abbott Laboratories | $44.22 | 2025 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $34.90 | 2019-2020 | |
| Axsome Therapeutics, INC. | $30.27 | 2023-2024 | Auvelity |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $30.05 | 2022 | |
| Boston Scientific Corporation | $21.85 | 2021 | |
| Melinta Therapeutics, LLC | $21.76 | 2019 | |
| Optinose US, INC. | $20.85 | 2022 | |
| Heron Therapeutics, INC. | $19.63 | 2021 | |
| Osiris Therapeutics INC. | $19.40 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $17.09 | 2022 | |
| Exact Sciences Corporation | $17.06 | 2025 | Cologuard Collection Kit |
| Corcept Therapeutics | $16.61 | 2020 | |
| Paratek Pharmaceuticals, INC. | $15.48 | 2023 | Nuzyra |
| E.R. Squibb & Sons, L.L.C. | $13.69 | 2023 | Eliquis |
| Novartis Pharmaceuticals Corporation | $12.92 | 2022 | |
| Biocryst US Sales Co., LLC | $12.76 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $12.11 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.59 | 2020 | |
| Daiichi Sankyo INC. | $11.31 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Blecha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.